Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Graier, T; Bordag, N; Weger, W; Laschober, N; Ratzinger, G; Jonak, C; Prillinger, K; Müllegger, R; Mlynek, A; Lange-Asschenfeldt, B; Häring, N; Hoetzenecker, W; Posch, C; Ellersdorfer, C; Sator, P; Gruber, B; Hofer, A; Gruber-Wackernagel, A; Legat, FJ; Großschädl, K; Gruber, V; Schadelbauer, E; Repelnig, M; Gressenberger, P; Widnig, A; Falkensteiner, K; Salmhofer, W; Wolf, P.
Real-world evidence on palmoplantar pustulosis: Patient characteristics, diagnostic challenges and predictive factors for treatment survival - a retrospective registry study.
Br J Dermatol. 2025; Doi: 10.1093/bjd/ljaf394
PubMed FullText FullText_MUG

 

Autor*innen der Med Uni Graz:
Bordag Natalie
Falkensteiner Katharina Theresia Christina
Graier Thomas
Gressenberger Paul Georg
Großschädl Katja
Gruber Viktoria
Gruber-Wackernagel Alexandra
Hofer Angelika
Lange-Asschenfeldt Bernhard
Laschober Nadine
Legat Franz
Muellegger Robert
Repelnig Maria-Lisa
Salmhofer Wolfgang
Schadelbauer Eva
Weger Wolfgang
Wolf Peter
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
INTRODUCTION: Little is known about the clinical characteristics, delay in diagnosis and treatment survival in patients with palmoplantar pustulosis (PPP). METHODS: This is a retrospective study using data from the Psoriasis Registry Austria (PsoRA). RESULTS: This study included data from 190 patients, who underwent 397 treatments. A substantial proportion of patients (53.6%) were initially misdiagnosed as having eczema with a mean (standard deviation) diagnostic delay of 2.8 years (4.8). Patients were predominantly female (74.2%) and smokers (77.6%). Patients were treated with biologics (49.9%), phototherapy (25.2) and conventional systemic therapies (24.9%). The median survival time (95% confidence interval) for all treatments was 0.6 years (0.5-0.8), with ustekinumab having the longest median survival time of 2.7 years (2.3 - upper limit not reached), surpassing all other therapies. However, this superiority disappeared after IL-23p19 inhibitors were introduced in Austria. Compared to biologics, conventional systemic treatments (hazard ratio [HR] 2.17, p < 0.001) and phototherapy (HR 4.43, p < 0.001) were associated with a significantly higher risk of treatment discontinuation. In the overall cohort, disease duration of ≥ 2 to < 10 years (HR 0.66, p = 0.049) and ≥ 10 years (HR 0.59, p = 0.004) significantly reduced the risk of treatment discontinuation, while concomitant plaque psoriasis significantly increased the risk for treatment discontinuation (HR 1.43, p = 0.049). In the biologic cohort, concomitant arthritis (HR 2.11, p = 0.002) and the presence of one comorbid disease (HR 2.34, p = 0.026) increased the risk for treatment discontinuation. Furthermore, gender, age at disease onset and smoking did not influence the risk of treatment discontinuation. CONCLUSION: The findings of this cohort suggest that more than half of patients experienced a diagnostic delay of several years due to an initial misdiagnosis. Among all therapies, the IL-12/23p40 inhibitor ustekinumab showed the longest treatment survival. However, its superiority diminished with the introduction of IL-23p19 inhibitors. Finally, shorter disease duration and concomitant plaque psoriasis was identified as a general risk factor for treatment discontinuation, while the presence of comorbidity and presence of concomitant psoriatic arthritis were identified as risk factors for discontinuation of biologic treatment.

© Med Uni Graz • Impressum